Introduction. The aim of this study was to review the performance of noninvasive prenatal testing (NIPT) for detection of trisomy 21, 18 and 13 (T21, T18 and T13) in a general pregnant population as well as to update the data on high-risk pregnancies. Material and methods. Systematic review and metaanalysis. PubMed, Embase and the Cochrane Library were searched. Methodological quality was rated using QUADAS and scientific evidence using GRADE. Summary measures of diagnostic accuracy were calculated using a bivariate random-effects model. Results. In a general pregnant population, there is moderate evidence that the pooled sensitivity is 0.993 (95% CI 0.955-0.999) and specificity was 0.999 (95% CI 0.998-0.999) for the analysis of T21. Pooled sensitivity and specificity for T13 and T18 was not calculated in this population due to the low number of studies. In a high-risk pregnant population, there is moderate evidence that the pooled sensitivities for T21 and T18 are 0.998 (95% CI 0.981-0.999) and 0.977 (95% CI 0.958-0.987) respectively, and low evidence that the pooled sensitivity for T13 is 0.975 (95% CI 0.819-0.997). The pooled specificity for all three trisomies is 0.999 (95% CI 0.998-0.999). Conclusions. This is the first meta-analysis using GRADE that shows that NIPT performs well as a screen for trisomy 21 in a general pregnant population. Although the false positive rate is low compared with first trimester combined screening, women should still be advised to confirm a positive result by invasive testing if termination of pregnancy is under consideration.
Introduction
Prenatal diagnosis, including screening and diagnosis of chromosome aberrations, has been offered in various forms as part of prenatal care during the last 40 years (1) . Diagnosis of chromosome aberrations requires either first-trimester chorionic villus sampling (CVS) or secondtrimester amniocentesis. However, these invasive procedures entail a miscarriage risk of 0.1-0.5% (2, 3) .
The presence of fetal cell-free DNA (cfDNA) in maternal circulation was first demonstrated by Lo et al. (4) . This finding led to the discovery that cfDNA obtained from maternal plasma could be used for fetal aneuploidy analysis, termed non-invasive prenatal testing (NIPT), a long-awaited improvement to reduce invasive procedures and accompanying miscarriage risk (5, 6) . NIPT for fetal aneuploidy analysis was introduced clinically in 2011 and is implemented in many countries worldwide; more than 2 million procedures have hitherto been performed (7) . Many studies have investigated analysis of cfDNA in maternal blood for detection of trisomies 21, 18 and 13 in women at high risk of aneuploidy, finding weighted pooled detection rates of 99.2% for trisomy 21 (T21), 96.3% for trisomy 18 (T18) and 91.0% for trisomy 13 (T13), as well as false-positive (FP) rates of 0.09% for T21 and 0.13% for T18 and T13 (8) . However, significant data from large studies on test performance in a general (i.e. average-risk) pregnant population have, until recently, been lacking (9, 10) . The objective of this metaanalysis was to update the data on high-risk pregnancies, including studies published up until April 2015 and, more importantly, present data concerning test performance in a general pregnant population at average risk of aneuploidy.
Material and methods

Systematic literature review
The Cochrane Collaboration definition of a systematic review was applied: "A systematic review attempts to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a given research question. Researchers conducting systematic reviews use explicit methods aimed at minimizing bias, in order to produce more reliable findings that can be used to inform decision making" (www.thecochranelib rary.com).
Literature search
The literature search included the databases PubMed, Embase, and the Cochrane Library up until 2 April 2015. The MeSH terms used were: "Down Syndrome", "Patau Syndrome", "Trisomy 18-Like Syndrome", "Chromosomes, Human, Pair 13", "Chromosomes, Human, Pair 18", and "Chromosomes, Human, Pair 21". In addition to MeSH terms, free-text words were used. For the search block regarding NIPT, only free-text terms were used, since there was no MeSH term for this concept. Detailed information about the search strategy can be found at http://www.sbu.se/upload/Publikationer/Content0/3/ NIPT/Bilaga%205%20S%C3%B6kstrategier.pdf.
Inclusion and exclusion criteria
Study selection was based on the following criteria using PICO (P -population, I -index test, C -control/reference test and O -outcome) (11). Population 1. Pregnant women at high risk of carrying a fetus with chromosome aberration (as determined by study authors, which could include women of varying risk level but defined as being at high risk because of different risk factors such as having been assessed to be high-risk by biochemical screening, first trimester combined screening (FTS), abnormal ultrasound scan or maternal age). journal, with reported, or data enabling calculation of, sensitivity and specificity. Exclusion criteria were RNA analysis, absence of primary data, study population <100 women and abstract/letter/review. Formal screening of search results against inclusion and exclusion criteria and risk of bias (quality) assessment was performed according to a prespecified protocol, PROSPERO registration number CRD42015020076, available at http://www.crd.york.ac. uk/PROSPERO/display_record.asp?ID=CRD42015020076.
Study selection and data extraction
Two authors (E.I., B.J.) individually reviewed all abstracts and made separate decisions based on inclusion and exclusion criteria. If at least one reviewer was considering an abstract for inclusion, the full-text article was reviewed. The reviewers individually decided whether a study could be included and contained data suitable for the subsequent analysis of clinical validity, and extracted the relevant data from each selected study using a standard form. The review form was designed to capture primary data, including study type, number of samples, FN and FP results, sensitivity and specificity levels, indeterminate cases, reference test (i.e. method used to confirm NIPT results), methodology and whether the study was sponsored by a commercial company. Inter-reviewer discrepancies were resolved by discussion. Where one of the review authors was a co-author of a selected study, M.H.A. and J.D. replaced that author in the quality review.
Rating quality of individual studies
The quality of each included study was rated as high, moderate or low using the QUADAS tool (12) . Only studies of high or moderate quality were considered good enough for grading of scientific evidence and conclusions.
Data synthesis
All statistical analyses were conducted using the metandi and midas commands in STATA 13 (StataCorp., College Station, TX, USA). A bivariate random-effects model was used to estimate average sensitivity, specificity, positive and negative likelihood ratios (LR + and LR À ) and diagnostic odds ratios (DOR), with 95% confidence intervals (CI). We also constructed the summary receiver operating characteristics (SROC) curve and the corresponding area under the curve (AUC) to summarize overall test performance (13) . We used coupled Forest plots and measures of variability (variances and covariance of sensitivity and specificity across studies) to assess between-study heterogeneity (14, 15) . We also undertook sensitivity analysis (excluding influential studies) to verify robustness of results. Finally, we assessed publication bias by plotting DOR against the effective sample size. With no bias, the plot should have an inverted symmetrical funnel shape. The degree of asymmetry was statistically assessed by regression of the logarithm of the DOR on the inverse of the square root of the effective sample size, weighted by effective sample size (16) .
Grading the scientific evidence across studies
The quality of scientific evidence of the outcomes of PICO was rated according to the four GRADE levels (17): High (⊕⊕⊕⊕) -we are very confident that the true effect lies close to that of the estimate of the effect; Moderate (⊕⊕⊕Ο) -we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low (⊕⊕ΟΟ) -our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; Very Low (⊕ΟΟΟ) -we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
The rated GRADE level is usually initially high, but confidence in the evidence may decrease stepwise during the analysis process for several reasons, including limitations in study design and/or quality, inconsistency or indirectness of results, imprecise estimates and probability of publication bias. Any disagreements on inclusion/ exclusion criteria, rated quality of individual studies or quality of evidence of test methods were resolved within the reviewer group by consensus.
Results
Selection of studies
In this systematic review, 882 abstracts met the search criteria; 453 of these were excluded based on inclusion and exclusion criteria. This resulted in 429 published full-text articles that were assessed regarding inclusion and exclusion criteria. During this step, 376 articles were excluded (Table S1 ). The scientific quality of the articles meeting the inclusion and exclusion criteria was assessed using the QUADAS tool (12) . Only studies with high or moderate quality were considered suitable to use for grading the quality of scientific evidence. Twenty-two were assessed as low-quality and were excluded from analysis (Table S2) , leaving 31 articles (32 studies) for further analysis ( Figure 1 ) . Two other studies (49, 50) were excluded because they reported on the same patients as in Jensen et al. (29) .
Study characteristics
The characteristics of the included studies are summarized in Tables S3-S5 . Twenty-three studies were prospective cohort studies (21, (25) (26) (27) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) and nine were case-control-studies (18) (19) (20) (22) (23) (24) (28) (29) (30) . The majority of sampling had occurred during the first trimester. Study designs varied and there were also variations in planning and execution, for example, samples may have been frozen or not and results were reported back to patients in some studies. In the majority of studies results were not reported back to patients. Generally, the number of failed analyses and need for repeat sampling are not well reported. Six of the 32 included studies did not report having a commercial partner (18, 25, 34, 39, 41, 51) .
The included studies were published from January 2011 to 2 April 2015. Nine studies were from centers offering NIPT for trisomies as part of a clinical service, with the results reported back to the patient (25, 26, 31, 39, 40, 42, (46) (47) (48) . The remaining 23 used biobanked samples (18) (19) (20) (21) (22) (23) (24) (27) (28) (29) (30) (32) (33) (34) (35) (36) (37) (38) 41, (43) (44) (45) . A reference test (inclusion criterion) -either an invasive prenatal test or postnatal examination (phenotype) -was used in all studies.
Based on QUADAS and taking into account the existence of a commercial partner and study design, all of the included studies were assessed as being of moderate quality (risk of bias graph shown in Table S6 ).
Five of the included studies were considered to investigate a general pregnant population (i.e. an average-risk population) (21, 33, 36, 37, 42) . Two studies included both a high-risk and an average-risk population (40, 47) . The remaining 25 studied a high-risk population. Thirteen of the 32 studies had a population exceeding 1000 pregnancies (21, 26, 29, 31, 33, 35, 36, 38, 39, 42, (46) (47) (48) .
In the case of the average-risk pregnant population, seven included studies reported on the performance of cfDNA analysis for T21, with a total of 156 TP T21 and 62,107 non-T21 TN singleton pregnancies (Table 1) (21, 33, 36, 37, 40, 42, 47) . For T18, there were a total of 15 TP cases and 21 989 TN singleton pregnancies in the included six studies (21, 33, 36, 37, 40, 42) . For T13, there were a total of six TP cases and 14 384 TN singleton pregnancies in the included five studies (Tables S7 and S8 (21, 36, 37, 40, 42) . In the high-risk pregnant population, there were 1839 TP T21 cases in total and the number of included singleton pregnancies exceeded 100 000 for all three trisomies (Table 1 ). The population in the study by Lau et al. (31) was classified as high-risk in our meta-analysis, since 46% of the women had an increased risk of carrying a fetus with a chromosome aberration; the median maternal age was 36. Dan et al. (26) report on 11 105 clinical NIPT analyses, but sensitivity and specificity calculations were only based on the 3000 samples for which results of an invasive prenatal test were available. In this case, we decided to re-calculate sensitivity and specificity, in order to include cases in which results of a postnatal clinical examination were available as a reference test. This made it possible to include 7524 pregnancies in our meta-analysis.
Meta-analyses
A significant level of heterogeneity was observed, with greater variance in sensitivity than specificity for T21 and T13 in the high-risk population but greater variance in specificity than sensitivity for T18 in the high-risk population and T21 in the average risk population (Table S9) . The corresponding prediction ellipses were not informative, as most studies generated estimates in the upper lefthand corner of the ROC plot.
The meta-analyses for T21 in the high-risk population yield a pooled sensitivity of 0.998 (95% CI 0.98-0.999) (Figure 2 ). In the average-risk population, i.e. the general pregnant population, pooled sensitivity was 0.993 (95% CI 0.955-0.999) (Figure 3 ). In the case of T18 in the high-risk population, pooled sensitivity was 0.977 (95% CI 0.958-0.987) (Figure 4 ) and the corresponding figure for T13 was 0.975 (95% CI 0.819-0.997) ( Figure 5 ). Sensitivity and specificity for T18 and T13 could not be calculated in the average-risk population due to the low number of studies ( Figure 6 ). For trisomies 21, 18 and 13 in the high-risk population, and for T21 in the averagerisk population, pooled specificity was 0.999 (95% CI 0.998-0.999) (Figures 2-5 ). Individual studies clustered in the upper left-hand corner of their corresponding SROC curves, with AUC values of 1 (95% CI 0.99-1.00) for trisomies 21, 18 and 13 in the high-risk population and 0.99 (95% CI 0.98-1.00) for T21 in the average-risk population. Other measures of diagnostic performance (LR + , LR À and DOR) are reported in Table S10 .
We found evidence of publication bias for T21 in the high-risk (p = 0.001) and average-risk populations (p = 0.018), as well as for T18 in the high-risk population (p = 0.010). There was no evidence of publication bias for T13 in the high-risk population (p = 0.085).
Grade
GRADE was used to determine confidence in the pooled estimates of sensitivity and specificity. The quality of evidence was considered to be moderate for T21 and T18 in the high-risk population, as well as for T21 in the average-risk population. The quality of evidence for T13 was limited in the high-risk population (Table 1) . No meta-analysis or grading for T13 and T18 in the averagerisk population was performed due to lack of data ( Figure 6 ).
False-positive and false-negative results
In this systematic review, the proportion of FP ranged between 2.7% (T21 in the high-risk population) and 30% (T13 in the general population) ( Table S7 ). The proportion of FN was generally very low, 0.01% at most (Table S8) .
Discussion
This systematic review and meta-analysis shows a pooled sensitivity of 0.993 (95% CI 0.955-0.999) and a pooled specificity of 0.999 (95% CI 0.998-0.999) for T21 detection with NIPT in the general pregnant population. Corresponding values for T13 and T18 could not be calculated due to the low number of studies as well as an insufficient number of trisomy cases, compared with nontrisomy cases, in the pool. The majority of studies on cfDNA analysis for aneuploidy detection have so far been performed in selected high-risk pregnant populations. The findings in this meta-analysis extend those of previous reviews by adding data from studies in general pregnant (average-risk) populations. Due to the recent publication of several additional studies, including two very large ones (36,47), our study has enhanced power to estimate the performance of cfDNA analysis in a general pregnant population. Moreover, there is now additional data on NIPT performance in a high-risk population. Zhang (2015) Yao (2014) Verweij (2013) Stumm (2014) Sparks (2012) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Norton (2012) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Guex (2013) Ehrich (2011) Dan (2012) Comas (2014) Chiu (2011) Bianchi (2012) Ashoor (2012) Alberti (2015) COMBINED Studyld Zhou (2014b)
Zhou (2014a) Zhang (2015) Yao (2014) Verweij (2013) Stumm (2014) Sparks (2012) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Norton (2012) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Guex (2013) Ehrich (2011) Dan (2012) Comas (2014) Chiu (2011) Bianchi (2012) Ashoor (2012) Alberti (2015) COMBINED Figure 2 . Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) for detecting trisomy 21 in a population at high risk of carrying a fetus with chromosome aberration. [Color figure can be viewed at wileyonlinelibrary.com] many trisomy cases as in a recent review on this topic by Gil et al. (8) . The review by Gil et al., with a total of 1051 T21 cases and 21 608 unaffected fetuses, showed weighted pooled detection rates of 99.2% for T21, 96.3% for T18, and 91.0% for T13 (8) .
The aim of applying GRADE is to ascertain how much confidence can be placed in a particular estimate of effect, whether the result will be sustainable and whether it is likely that new research will change the evidence. There is moderate quality of evidence, according to GRADE, underlying the pooled sensitivity of 0.993 and the pooled specificity of 0.999 for T21 detection in the general pregnant population, i.e. this result is likely to be close to the true effect. However, further improvement of cfDNA analysis may of course change these figures by enhancing method performance. GRADE assessment also demonstrates moderate quality of evidence for T21 and T18 detection in the high-risk pregnant population. Due to study quality and imprecision, the quality of evidence for T13 detection failed to reach the moderate level and was found to be low in the high-risk population. For T18 and T13, it was not possible to determine the quality of evidence in the general population due to insufficient data for these low-prevalence trisomies. Deeks' symmetry test suggested the existence of publication bias in three of the four meta-analyses (T21 in the high-risk and averagerisk populations, and T18 in the high-risk population, but not T13 in the high-risk population). The cfDNA technique was developed in a commercial setting with an early introduction to the clinical market. Only six of the 32 included studies did not report having a commercial partner (18, 25, 31, 34, 39, 41) . The general impression is that commercial interests may affect results, and the meta-analysis by Taylor et al. (9) confirms the presence of publication bias. Nonetheless, we have chosen not to degrade these findings according to the GRADE protocol.
The two recently published meta-analyses that show separate data from a general pregnant population (average-risk) differ from ours in outcome (9, 10) . The pooled sensitivity in the general pregnant population is higher in our meta-analysis (0.993) than in the systematic review by Taylor et al. (0.959) (9) . Our reviews differ in some aspects, such as inclusion and exclusion criteria, where we chose to exclude studies judged to be at high risk of bias Nicolaides (2012) Bianchi (2014) Song (2013) Pergament (2014) Norton (2015) Zhang (2015) Nicolaides (2012) Bianchi ( (low-quality studies), from the meta-analysis using QUA-DAS. In addition, we do not report pooled sensitivity for T13 and T18 detection in the general pregnant population due to the low number of studies and limited data.
The main difference of our data compared with Mackie et al. (10) is the huge discrepancy when it comes to the number of patients included in the two different subpopulations of high and normal risk (Table 1) . This might at least partly explain the different outcomes, our meta-analysis showing a difference in sensitivity for highcompared with normal risk population (0.998 compared with 0.993), a difference that the meta-analysis by Mackie et al. does not show. In addition, our analysis shows a somewhat higher sensitivity for T21 analysis in a high-risk population (0.998) compared with Mackie et al. (0.994) (10) . The majority of the included studies were performed not in a clinical context but retrospectively, using frozen biobanked plasma samples, and the results were not reported back to the patient (18) (19) (20) (22) (23) (24) (27) (28) (29) (30) (32) (33) (34) 37, 38, 41, (43) (44) (45) . This might have affected test performance when applied clinically, for example the no-result rate may have been underestimated. However, several larger studies from a clinical setting have been published during 201-2015 and the number of included patients in clinical studies thus by far exceeds the number of patients in the biobank studies (25, 26, 31, 35, 36, 39, 40, 42, (46) (47) (48) . This limits the risk of such clinical consequences. The percentages of samples not generating a report back to the referring doctor is one aspect of cfDNA clinical usefulness that is insufficiently reported in most of the studies. There can be numerous reasons for this at different levels of the process, where sample analysis might be problematic: a sample might not fulfill the preanalytic quality criteria (such as inadequate blood volume, incorrect labeling of tubes and delay in arrival at the laboratory) or analytic quality criteria (such as low fetal fraction or assay failure). In the studies performed in a clinical-like setting, an additional sample was required in 0.9-4.6% of cases (21, 24, 26, 31, 35, 36, 39, 42, 47, 48) , in addition to the samples failing to meet the pre-analytical criteria. None of the studies included in this meta-analysis was analyzed by "intention-to-diagnose", which would have made it easier to interpret the findings from a clinical perspective. The NIPT assay used for trisomy detection is Zhang (2015) Yao (2014) Stumm (2014) Sparks (2012) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Norton (2012) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Chen (2011) Dan (2012) Guex (2013) Bianchi (2012) Ashoor ( Zhang (2015) Yao (2014) Stumm (2014) Sparks (2012) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Norton (2012) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Chen (2011) Dan (2012) Guex (2013) Bianchi (2012) Ashoor (2012 Zhang (2015) Yao (2014) Stumm (2014) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Guex (2013) Chen (2011) Bianchi (2012) Ashoor (2013) Zhou (2014a) Zhang (2015) Yao (2014) Stumm (2014) Song (2015) Shaw (2014) Quezada (2015) Porreco (2014) Pergament (2014) Nicolaides (2013) Liang (2013) Lau (2014) Jiang (2012) Jensen (2013) Guex (2013) Chen (2011) Bianchi (2012) Ashoor ( based on new sequence technology and three different approaches are in clinical use: massive parallel (shotgun) sequencing (MPSS), targeted massive parallel sequencing (t-MPS), and t-MPS with the use of single nucleotide polymorphisms (SNP), with the different respective pros and cons. The majority of the included studies used MPSS, followed by t-MPS-and SNP-based analysis. In this review, we did not study the approaches separately. This is the first meta-analysis using GRADE that includes a sufficient sample size to permit the conclusion that NIPT performs well as a screen for fetal T21 in a general pregnant population. More data are needed concerning T18 and T13. As the data in this meta-analysis suggest nearly equally good test performance in the general population, the scenario of using cfDNA instead of FTS will be increasingly considered. This approach will have the advantage of detecting more aneuploid pregnancies, nearly eliminating false reassurance and significantly reducing the number of women requiring an invasive test for confirmation. The major limiting factor for this development is the cost of the NIPT assay, which is still at least double the cost of FTS. Moreover, although the FP rate is low compared with FTS, women should still be advised to confirm a positive NIPT result by invasive testing if termination of pregnancy is under consideration.
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